Overview
Neonatal colibacillosis, primarily caused by Escherichia coli, manifests as systemic infections in young animals, often leading to significant morbidity and mortality, particularly affecting the respiratory and cardiovascular systems 12.Diagnosis
Clinical signs include lethargy, depression, diarrhea, and respiratory distress.
Post-mortem findings often reveal airsacculitis, pericarditis, and occasionally perihepatitis.
Laboratory tests may include bacterial culture and sensitivity from affected tissues 1.Management
First-line treatments: Antibiotics targeting E. coli, such as bacitracin methylene disalicyclate (BMD) and newer alternatives like TAMUS 2032 (BT). Specific dosing not detailed for neonatal use.
Adjunctive measures: Environmental management to reduce stress and optimize housing conditions, including temperature control 1.Special Populations
Pediatrics: Neonates are particularly vulnerable; early intervention is crucial 12.
Comorbidities: Sequential exposure to other pathogens (e.g., Newcastle disease virus, Bordetella avium) can exacerbate colibacillosis severity 2.Key Recommendations
Implement prophylactic use of antimicrobial agents like TAMUS 2032 to reduce mortality and improve growth parameters in at-risk populations (Evidence: Moderate) 1.
Monitor and manage environmental factors to prevent conditions conducive to colibacillosis outbreaks (Evidence: Expert opinion) 1.
Consider sequential pathogen exposure history when assessing risk for severe colibacillosis in neonatal populations (Evidence: Moderate) 2.References
1 Jiang YW, Sims MD, Conway DP. The efficacy of TAMUS 2032 in preventing a natural outbreak of colibacillosis in broiler chickens in floor pens. Poultry science 2005. link
2 Pierson FW, Larsen CT, Domermuth CH. The production of colibacillosis in turkeys following sequential exposure to Newcastle disease virus or Bordetella avium, avirulent hemorrhagic enteritis virus, and Escherichia coli. Avian diseases 1996. link